199294-70-7 Usage
Uses
Used in Pharmaceutical Industry:
AMG-337 is used as an anti-cancer agent for targeting the c-Met receptor, which is often overexpressed in various types of cancer cells. Its ability to inhibit the c-Met receptor makes it a potential therapeutic option for cancer patients with c-Met overexpression, offering a targeted approach to cancer treatment.
Used in Clinical Trials:
AMG-337 is currently being evaluated in clinical trials for the treatment of various types of solid tumors. Preclinical studies have shown promising results, and its progression to clinical trials indicates its potential as a viable treatment option for cancer patients.
Used in Cancer Research:
As a kinase inhibitor with specificity for the c-Met receptor, AMG-337 is also used in cancer research to better understand the role of the c-Met receptor in cancer development and progression. This knowledge can contribute to the development of more effective and targeted cancer therapies in the future.
Check Digit Verification of cas no
The CAS Registry Mumber 199294-70-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,2,9 and 4 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 199294-70:
(8*1)+(7*9)+(6*9)+(5*2)+(4*9)+(3*4)+(2*7)+(1*0)=197
197 % 10 = 7
So 199294-70-7 is a valid CAS Registry Number.
199294-70-7Relevant academic research and scientific papers
Efficacious, orally bioavailable thrombin inhibitors based on 3- aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates
Sanderson, Philip E. J.,Lyle, Terry A.,Cutrona, Kellie J.,Dyer, Dona L.,Dorsey, Bruce D.,McDonough, Colleen M.,Naylor-Olsen, Adel M.,Chen, I.-Wu,Chen, Zhongguo,Cook, Jacquelynn J.,Cooper, Carolyn M.,Gardell, Stephen J.,Hare, Timothy R.,Krueger, Julie A.,Lewis, S. Dale,Lin, Jiunn H.,Lucas Jr., Bobby J.,Lyle, Elizabeth A.,Lynch Jr., Joseph J.,Stranieri, Maria T.,Vastag, Kari,Yan, Youwei,Shafer, Jules A.,Vacca, Joseph P.
, p. 4466 - 4474 (2007/10/03)
We have addressed the key deficiency of noncovalent pyridinone acetamide thrombin inhibitor L-374,087 (1), namely, its modest half-lives in animals, by making a chemically stable 3-alkylaminopyrazinone bioisostere for its 3- sulfonylaminopyridinone core.
